We are pleased to announce that icometrix is now a GE HealthCare company. Click here to learn more.
.png)
Join us for these sessions
JUNE 12
7:30AM & 4:15PM
ARIA-E Lesion Topography in Real-World ARIA Monitoring data from 4 US Sites
POSTER SESSION
NUNO BARROS
JUNE 14
7:30AM & 4:15PM
Automated Mri Volumetry (icobrain dm) Enhances Risk Stratification In Mci Independent Of Amyloid Status
POSTER SESSION
NUNO BARROS
JUNE 15
7:30AM & 4:15PM
Real-world Usability And Clinical Impact Of AI-assisted MRI ARIA Monitoring Across Diverse Healthcare Settings
POSTER SESSION
NUNO BARROS
Learn more about icobrain aria*
icobrain aria can be used to assess side effects to amyloid-targeting therapies for Alzheimer's disease, known as amyloid-related imaging abnormalities (ARIA). It helps improve clinical confidence when elevating the presence of parenchymal vasogenic edema, gyral swelling and sulcal effusion.
Latest news
A New Era in Alzheimer’s Disease Care: Transforming Neurology with AI
10 June 2026 at 7:03:34 am
A Shared Language for ARIA: Standardizing Alzheimer’s Imaging in the Age of New Therapies with RSNA
10 June 2026 at 7:03:58 am
Enhancing Alzheimer's Care: The Collaboration Between InRAD and icometrix
10 June 2026 at 7:04:25 am
Get reimbursement assistance at RSNA
More than 30 U.S. insurers have successfully processed claims for CPT III® codes 0865T & 0866T for icobrain analyses.
Our reimbursement team is here to guide you every step of the way with billing and coding guides, medical necessity templates, prior authorization checklists, and appeal support.
Book your meeting during RSNA and indicate that you’re interested in reimbursement support - our team will be ready to discuss your specific case and provide tailored resources.
Key scientific publications
*icobrain aria is 510(k) cleared. CE marked as part of icobrain mr. Not available in all markets.